Tel:
+49 (0)241 95 163 153
Fax:
+49 (0)241 95 163 155
E-Mail:
orders@anticorps-enligne.fr

Recombinant CD274 (Atezolizumab Biosimilar) anticorps

Reactivité: Humain FACS, in vivo Hôte: Souris Monoclonal unconjugated Recombinant Antibody
N° du produit ABIN7200666
  • Antigène Tous les produits CD274 (Atezolizumab Biosimilar)
    CD274 (Atezolizumab Biosimilar)
    Type d'anticorp
    Recombinant Antibody
    Reactivité
    Humain
    Hôte
    • 1
    • 1
    Souris
    Clonalité
    • 2
    Monoclonal
    Conjugué
    • 2
    Cet anticorp CD274 (Atezolizumab Biosimilar) est non-conjugé
    Application
    Flow Cytometry (FACS), In vivo Studies (in vivo)
    Fonction
    Atezolizumab Biosimilar, Human PD-L1 Monoclonal Antibody
    Specificité
    The in vivo grade atezolizumab biosimilar specifically binds to the human PDL1 protein.
    Attributs du produit
    Recombinant Humanized IgG1 Monoclonal Antibody.
    Purification
    Protein A affinity column
    Pureté
    > 95% by SDS-PAGE under reducing conditions and HPLC.
    Stérilité
    0.2 μm filtered
    niveau d'endotoxine
    < 1 EU per 1 mg of the protein by the LAL method.
    Immunogène
    The anti-human programmed cell death ligand 1 (PD-L1) monoclonal antibody atezolizumab biosimilar was produced in the atezolizumab biosimilar CHO stable cell line.
    Isotype
    IgG1 kappa
  • Indications d'application
    ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by atezolizumab.
    Restrictions
    For Research Use only
  • Format
    Liquid
    Concentration
    1 mg/mL
    Buffer
    PBS, pH 7.4, no stabilizers or preservatives.
    Agent conservateur
    Without preservative
    Conseil sur la manipulation
    Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
    Stock
    -20 °C
    Stockage commentaire
    12 months from date of receipt, -20 to -70°C as supplied. 1 month from date of receipt, 2 to 8°C as supplied.
    Date de péremption
    12 months
  • Antigène
    CD274 (Atezolizumab Biosimilar)
    Abstract
    CD274 (Atezolizumab Biosimilar) Produits
    Synonymes
    anticorps B7-H, anticorps B7H1, anticorps PD-L1, anticorps PDCD1L1, anticorps PDCD1LG1, anticorps PDL1, anticorps CD274 molecule, anticorps CD274
    Classe de substances
    Biosimilar
    Sujet
    What is Atezolizumab biosimilar research grade? Atezolizumab is a humanized monoclonal antibody directed against the human protein ligand PD-L1, with potential immune checkpoint inhibitory and antineoplastic activities. Atezolizumab is an Fc-engineered, humanized, monoclonal antibody (IgG1κ isotype). Atezolizumab biosimilar uses the same protein sequences as the therapeutic antibody atezolizumab.

    PD-L1 (B7-H1 or CD274, programmed cell death ligand 1) and PD-L2 (B2-DC or CD273, programmed cell death ligand 2) are the two ligands for the receptor PD-1 (CD279, programmed death 1). PD-L1 is an immune checkpoint molecule expressed on both tumor cells and certain immune cells. The binding of PD-L1 to its receptors PD-1 or B7.1 on activated T cells causes an inhibitory signal to suppress their production in the lymph nodes, thereby preventing immune responses to events such as pregnancy or autoimmune disease. This pathway is also utilized by cancer cells to evade the immune system through evasion of anti-tumor T-cell response. Furthermore, over-expression of PD-L1 and PD-1 has been linked to increased tumor aggressiveness and poorer prognosis. Atezolizumab binds directly and selectively to PD-L1 and blocks interaction with both PD-1 and B7.1 receptors, thus reinvigorates and enhances the body’s adaptive anti-cancer activity. Disrupting the PD-L1/B7.1 interaction may also enhance T-cell priming, which could result in increased duration of response and survival.
Vous êtes ici:
Support technique